Analyst Price Target is $46.80
▼ -3.21% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Vericel in the last 3 months. The average price target is $46.80, with a high forecast of $55.00 and a low forecast of $39.00. The average price target represents a -3.21% upside from the last price of $48.35.
Current Consensus is
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Vericel. This Buy consensus rating has held steady for over two years.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Read More
